Difference between revisions of "Programmed death-ligand 1"
Jump to navigation
Jump to search
(+IHC) |
|||
| Line 45: | Line 45: | ||
**Durvalumab (''Imfinzi'', AstraZeneca). | **Durvalumab (''Imfinzi'', AstraZeneca). | ||
**Avelumab (''Bavencio'', Merck/Pfizer). | **Avelumab (''Bavencio'', Merck/Pfizer). | ||
===Anti-PD-L1 drugs - use=== | ===Anti-PD-L1 drugs - use=== | ||
Revision as of 03:57, 9 November 2018
Programmed death-ligand 1, commonly abbreviated PD-L1, is a protein with an important role in immune system regulation and cancer.
Normally, PD-L1 on cells binds with programmed cell death 1 on the T lymphocytes.[1]
PD-L1 is also known as CD274.[2]
General
- In theory, positive PD-L1 immunostaining predicts response to anti-PD-L1 drugs.[3]
- Carcinoma cell is considered "PD-L1 positive" if the cell membrane is partially or completely stained. [4]
- It is, however, more complex than that. Some tumour types are invariably positive, e.g. classical Hodgkin lymphoma, so testing is unhelpful. In contrast, tumors such as malignant melanoma respond regardless of PD-L1 immunoexpression.
- The plethora of companion diagnostics developed for each PD-1/ PD-L1 inhibitor has created challenges, as these assays include different IHC antibody clones, staining protocols and platforms, scoring systems, and cutoffs for defining positivity.
- Nivolumab - 28-8 (Dako)
- Pembrolizumab - 22C3 (Dako)
- Aterolizumab - SP142 (Ventana)
- Durvalumab - SP263 (Ventana)
- Avelumab - 73-10 (Dako)
Background
Cytotoxic T cell function is regulated by receptor pairs found on the tumour and lymphocyte:[1]
| Function | Tumour cell | T cell |
|---|---|---|
| Antigen presentation | MHC | TCR |
| Signal inhibition | PD-1 | PD-L1 (CD274), PD-L2 (CD273) |
Prognosis
- Good prognosis - in high-grade ovarian serous carcinoma, associated with tumour-infiltrating lymphocytes.[5]
Drugs - Immune checkpoint inhibitors
- PD-1 inhibitors:
- Nivolumab (Opdivo, Bristol-Myers Squibb).
- Pembrolizumab (Keytruda, Merck).
- PD-L1 inhibitors:
- Atezolizumab (Tecentriq, Roche).[3]
- Durvalumab (Imfinzi, AstraZeneca).
- Avelumab (Bavencio, Merck/Pfizer).
Anti-PD-L1 drugs - use
PD-L1 antibodies are being used to treat:[6]
- Malignant melanoma.
- Non-small cell lung cancer.
- Associated with response predicted by tumour-infiltrating lymphocytes and PD-L1 IHC positivity of the tumour cells.[3]
- Renal cell carcinoma.
- Urothelial carcinoma.
- Merkel cell carcinoma
- Acute myeloid leukemia
See also
References
- ↑ 1.0 1.1 Ribas, A. (Jun 2012). "Tumor immunotherapy directed at PD-1.". N Engl J Med 366 (26): 2517-9. doi:10.1056/NEJMe1205943. PMID 22658126.
- ↑ Online 'Mendelian Inheritance in Man' (OMIM) 605402
- ↑ 3.0 3.1 3.2 Fehrenbacher, L.; Spira, A.; Ballinger, M.; Kowanetz, M.; Vansteenkiste, J.; Mazieres, J.; Park, K.; Smith, D. et al. (Mar 2016). "Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.". Lancet. doi:10.1016/S0140-6736(16)00587-0. PMID 26970723.
- ↑ Scheel, AH.; Dietel, M.; Heukamp, LC.; Jöhrens, K.; Kirchner, T.; Reu, S.; Rüschoff, J.; Schildhaus, HU. et al. (Oct 2016). "Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas.". Mod Pathol 29 (10): 1165-72. doi:10.1038/modpathol.2016.117. PMID 27389313.
- ↑ Webb, JR.; Milne, K.; Kroeger, DR.; Nelson, BH. (May 2016). "PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.". Gynecol Oncol 141 (2): 293-302. doi:10.1016/j.ygyno.2016.03.008. PMID 26972336.
- ↑ Gandini, S.; Massi, D.; Mandalà, M. (Apr 2016). "PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis.". Crit Rev Oncol Hematol 100: 88-98. doi:10.1016/j.critrevonc.2016.02.001. PMID 26895815.